These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 11231710)

  • 21. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.
    Carias C; Reed C; Kim IK; Foppa IM; Biggerstaff M; Meltzer MI; Finelli L; Swerdlow DL
    PLoS One; 2015; 10(7):e0132922. PubMed ID: 26230271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years.
    Nichol KL; Goodman M
    Vaccine; 2002 May; 20 Suppl 2():S21-4. PubMed ID: 12110251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential economic value of influenza vaccination for healthcare workers in The Netherlands.
    Meijboom MJ; Riphagen-Dalhuisen J; Hak E
    Influenza Other Respir Viruses; 2018 Jul; 12(4):457-464. PubMed ID: 29624882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effectiveness of vaccination against influenza in healthy, working adults.
    Nichol KL; Lind A; Margolis KL; Murdoch M; McFadden R; Hauge M; Magnan S; Drake M
    N Engl J Med; 1995 Oct; 333(14):889-93. PubMed ID: 7666874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficiency of influenza vaccination in the working population in Spain].
    de Juanes JR; Cisterna R; Sanz J; Magaz S; Badia X
    Gac Sanit; 2006; 20(2):101-7. PubMed ID: 16753086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
    Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review.
    Anderson LJ; Shekelle P; Keeler E; Uscher-Pines L; Shanman R; Morton S; Aliyev G; Nuckols TK
    Am J Prev Med; 2018 Feb; 54(2):299-315. PubMed ID: 29362167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.
    Prosser LA; Lavelle TA; Fiore AE; Bridges CB; Reed C; Jain S; Dunham KM; Meltzer MI
    PLoS One; 2011; 6(7):e22308. PubMed ID: 21829456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US.
    Peasah SK; Meltzer MI; Vu M; Moulia DL; Bridges CB
    PLoS One; 2019; 14(4):e0213499. PubMed ID: 31034485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic costs of influenza-related work absenteeism.
    Akazawa M; Sindelar JL; Paltiel AD
    Value Health; 2003; 6(2):107-15. PubMed ID: 12641861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.
    Khazeni N; Hutton DW; Garber AM; Hupert N; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):829-39. PubMed ID: 20008759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company.
    Burckel E; Ashraf T; de Sousa Filho JP; Forleo Neto E; Guarino H; Yauti C; Barreto F de B; Champion L
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):563-76. PubMed ID: 10662481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.
    Smith KJ; Nowalk MP; Lin CJ; Zimmerman RK
    Hum Vaccin Immunother; 2017 Oct; 13(10):2207-2212. PubMed ID: 28829719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness analysis of Year 2 of an elementary school-located influenza vaccination program-Results from a randomized controlled trial.
    Yoo BK; Humiston SG; Szilagyi PG; Schaffer SJ; Long C; Kolasa M
    BMC Health Serv Res; 2015 Nov; 15():511. PubMed ID: 26573461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimated Cost Effectiveness of Influenza Vaccination for Emergency Medical Services Professionals.
    Hubble MW; Renkiewicz GK
    West J Emerg Med; 2021 Oct; 22(6):1317-1325. PubMed ID: 34787557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.